Search - tctmd.com

Displaying 1 - 18 of 18

Sort: Relevancy | Date

News Daily News

No Anticoagulation Benefit, High Bleeding Risk Seen in Patients With Secondary A-fib

Michael O'Riordan

September 29, 2017

News Daily News

Final CMS Decision Memo for Watchman Dumps Controversial Warfarin Contraindication

Shelley Wood

February 08, 2016

News Daily News

急性心肌梗死很少是由冠状动脉栓塞引起的，往往与房颤有联系

L.A. McKeown

July 08, 2015

News Daily News

Substantial Minority of Low-Risk A-fib Patients Still Given Anticoagulants

Salynn Boyles

April 28, 2015

News Conference News ESC 2013

New Alternatives Match Efficacy to Warfarin in High-Risk Subgroups

Caitlin E. Cox

September 03, 2013

News Daily News

控制良好的华法林不会降低三联疗法出血风险

August 30, 2013

News Daily News

El Riesgo Hemorrágico de la Terapia Triple No lo Atenúa la Warfarina Bien Controlada

August 30, 2013

News Daily News

Bleeding Risk of Triple Therapy Not Attenuated by Well-Controlled Warfarin

August 30, 2013

News Daily News

Apixaban Reduce el Índice de Hospitalizaciones compardo con la Aspirina en Pacientes con Fibrilación Auricular

Jason Kahn

August 05, 2013

News Daily News

Apixaban Lowers Hospitalization Rate vs. Aspirin in A-fib Patients

Jason Kahn

August 05, 2013

News Daily News

El Apixaban Superior a la Warfarin con independencia del Tipo y Duración de la FA

May 13, 2013

News Daily News

Apixaban Superior to Warfarin Regardless of A-fib Type, Duration

May 13, 2013

News Daily News

Rivaroxaban May be Cost-Effective for A-fib Patients

L.A. McKeown

June 06, 2012

News Daily News

El Rivaroxaban podría ser Rentable en Pacientes con Fibrilación Auricular

L.A. McKeown

June 06, 2012

News Daily News

Watchman Works Just as Well Without Warfarin-Protected Transition

June 01, 2012

News Daily News

El Watchman Funciona Igual de Bien sin Transición Protegida con Warfarina

June 01, 2012

News Conference News

Novel Anticoagulants Showing Benefits in A-fib Subgroups

August 29, 2011

News Conference News

Apixaban Bests Warfarin in Stroke Prevention for Atrial Fib

August 28, 2011

Advertisement

No Anticoagulation Benefit, High Bleeding Risk Seen in Patients With Secondary A-fib

Final CMS Decision Memo for Watchman Dumps Controversial Warfarin Contraindication

急性心肌梗死很少是由冠状动脉栓塞引起的，往往与房颤有联系

Substantial Minority of Low-Risk A-fib Patients Still Given Anticoagulants

New Alternatives Match Efficacy to Warfarin in High-Risk Subgroups

控制良好的华法林不会降低三联疗法出血风险

El Riesgo Hemorrágico de la Terapia Triple No lo Atenúa la Warfarina Bien Controlada

Bleeding Risk of Triple Therapy Not Attenuated by Well-Controlled Warfarin

Apixaban Reduce el Índice de Hospitalizaciones compardo con la Aspirina en Pacientes con Fibrilación Auricular

Apixaban Lowers Hospitalization Rate vs. Aspirin in A-fib Patients

El Apixaban Superior a la Warfarin con independencia del Tipo y Duración de la FA

Apixaban Superior to Warfarin Regardless of A-fib Type, Duration

Rivaroxaban May be Cost-Effective for A-fib Patients

El Rivaroxaban podría ser Rentable en Pacientes con Fibrilación Auricular

Watchman Works Just as Well Without Warfarin-Protected Transition

El Watchman Funciona Igual de Bien sin Transición Protegida con Warfarina

Novel Anticoagulants Showing Benefits in A-fib Subgroups

Apixaban Bests Warfarin in Stroke Prevention for Atrial Fib

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content